Abstract:The Wnt/β-catenin signaling pathway plays important roles in embryonic development and tissue homeostasis. Wnt signaling is induced, and β -catenin is activated, associated with the development and progression of renal fibrosis. Wnt/ β -catenin controls the expression of various downstream mediators such as snail1, twist, matrix metalloproteinase-7, plasminogen activator inhibitor-1, transient receptor potential canonical 6, and renin-angiotensin system components in epithelial cells, fibroblast, and macrophages. In addition, Wnt/ β -catenin is usually intertwined with other signaling pathways to promote renal interstitial fibrosis. Actually, given the crucial of Wnt/ β -catenin signaling in renal fibrogenesis, blocking this signaling may benefit renal interstitial fibrosis. There are several antagonists of Wnt signaling that negatively control Wnt activation, and these include soluble Fzd-related proteins, the family of Dickkopf 1 proteins, Klotho and Wnt inhibitory factor-1. Furthermore, numerous emerging small-molecule β -catenin inhibitors cannot be ignored to prevent and treat renal fibrosis. Moreover, we reviewed the knowledge focusing on anti-fibrotic effects of natural products commonly used in kidney disease by inhibiting the Wnt/ β -catenin signaling pathway. Therefore, in this review, we summarize recent advances in the regulation, downstream targets, role, and mechanisms of Wnt/ β -catenin signaling in renal fibrosis pathogenesis. We also discuss the therapeutic potential of targeting this pathway to treat renal fibrosis; this may shed new insights into effective treatment strategies to prevent and treat renal fibrosis.

Discovery of Natural Products Alleviating Renal Fibrosis with a Viscosity-Responsive Molecular Probe

Potential Therapeutic Medicines for Renal Fibrosis: Small-molecule Compounds and Natural Products.

Natural products in traditional Chinese medicine: molecular mechanisms and therapeutic targets of renal fibrosis and state-of-the-art drug delivery systems

Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment

Natural Products Against Renal Fibrosis via Modulation of SUMOylation

Emerging Roles Of Long Non-Coding Rnas In Renal Fibrosis

LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation

Defining Therapeutic Targets for Renal Fibrosis: Exploiting the Biology of Pathogenesis

Druggability of lipid metabolism modulation against renal fibrosis

Natural Products in Liver Fibrosis Management: A Five-year Review

Drug repurposing screens to identify potential drugs for chronic kidney disease by targeting prostaglandin E2 receptor

Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression

Exosome-mediated renal protection: Halting the progression of fibrosis

Discovering a New Drug Against Acute Kidney Injury by Using a Tailored Photoacoustic Imaging Probe

TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis

Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis

Platelet membrane biomimetic nanoparticle-targeted delivery of TGF-β1 siRNA attenuates renal inflammation and fibrosis

Targeting the Wnt/β-Catenin Signaling Pathway as a Potential Therapeutic Strategy in Renal Tubulointerstitial Fibrosis

A comprehensive review of natural products to fight liver fibrosis: Alkaloids, terpenoids, glycosides, coumarins and other compounds

Design, synthesis and biological evaluation studies of novel anti-fibrosis agents bearing sulfoxide moiety

Bisdemethoxycurcumin Protects Against Renal Fibrosis Via Activation of Fibroblast Apoptosis